TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.

Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.

Boehringer discontinues brigimadlin while others continue to struggle.

Tough equity markets as well as competitor developments prompt a narrowed focus.

The FDA will rule on a low dose of zongertinib in the summer.

While Cogent joins the FGFR party.

But could toxicity be holding back filing plans?

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.